lunes, 4 de diciembre de 2017

Molecular Genomic Testing for Breast Cancer: Utility for Surgeons. - PubMed - NCBI

Molecular Genomic Testing for Breast Cancer: Utility for Surgeons. - PubMed - NCBI



 2017 Nov 20. doi: 10.1245/s10434-017-6254-z. [Epub ahead of print]

Molecular Genomic Testing for Breast Cancer: Utility for Surgeons.

Abstract

Molecular genomic testing provides clinicians with both prognostic and (sometimes) predictive information that can help individualize treatment and decrease the risk of over- or under-treatment. We review the genomic tests that are currently available for clinical use in management of breast cancer, discuss ongoing research related to validating and expanding their utility in different patient populations, and explain why it is important for surgeons to know how to incorporate these tools into their clinical practice in order to individualize patient treatment, reduce unnecessary morbidity, and, accordingly, improve outcomes.

PMID:
 
29159748
 
DOI:
 
10.1245/s10434-017-6254-z

No hay comentarios:

Publicar un comentario